Cabozantinib After an Immune Checkpoint Inhibitor in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
Target Oncol 2020 Jul 15;[EPub Ahead of Print], R Iacovelli, C Ciccarese, G Facchini, M Milella, F Urbano, U Basso, U De Giorgi, R Sabbatini, D Santini, R Berardi, M Santoni, S Bracarda, F Massari, C Masini, M De Tursi, R Ricotta, S Buti, F Zustovich, P Sepe, S Rossetti, M Maruzzo, E Cortesi, G Tortora, G ProcopioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.